Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease

NCT01968031 is registered in ClinicalTrials.gov with Kyowa Kirin Co., Ltd. as lead sponsor.

NCT NCT01968031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01968031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease
Lead sponsor
Kyowa Kirin Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2013
Completion date
October 31, 2016
Enrollment
613 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson's disease